MoneyWorks4Me

Hikal gets EIR from USFDA for API unit in Bangalore

04 Nov 2019 Evaluate

Hikal has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its API Unit located at Jigani, Bangalore for the inspection conducted in July 2019. The inspection resulted in one minor FDA Form 483 which was closed out immediately.

Hikal is engaged in R&D, manufacturing and marketing of fine chemicals for the Pharmaceutical and Agrochemical industries.

Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..